This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ono, M. Articles by Kuwano, M. Search for Related Content PubMed PubMed Citation Articles by Ono, M. Articles by Kuwano, M.

Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs

Authors' Affiliations: ¹ Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan and ² Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan

Requests for reprints: Mayumi Ono, Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Phone: 81-92-642-6098; Fax: 81-92-642-6203; E-mail: mayumi{at}biochem1.med.kyushu-u.ac.jp.

The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, including EGFR, HER2/erbB2, and HER3/erbB3, is an attractive target for antitumor strategies. Aberrant EGFR signaling is correlated with progression of various malignancies, and somatic tyrosine kinase domain mutations in the EGFR gene have been discovered in patients with non–small cell lung cancer responding to EGFR-targeting small molecular agents, such as gefitinib and erlotinib. EGFR overexpression is thought to be the principal mechanism of activation in various malignant tumors. Moreover, an increased EGFR copy number is associated with improved survival in non–small cell lung cancer patients, suggesting that increased expression of mutant and/or wild-type EGFR molecules could be molecular determinants of responses to gefitinib. However, as EGFR mutations and/or gene gains are not observed in all patients who respond partially to treatment, alternative mechanisms might confer sensitivity to EGFR-targeting agents. Preclinical studies showed that sensitivity to EGFR tyrosine kinase inhibitors depends on how closely cell survival and growth signalings are coupled with EGFR, and also with HER2 and HER3, in each cancer. This review also describes a possible association between EGFR phosphorylation and drug sensitivity in cancer cells, as well as discussing the antiangiogenic effect of gefitinib in association with EGFR activation and phosphatidylinositol 3-kinase/Akt activation in vascular endothelial cells.

This article has been cited by other articles:

				X. Liu, W. K. K. Wu, L. Yu, Z. J. Li, J. J. Y. Sung, S. T. Zhang, and C. H. Cho Epidermal Growth Factor-Induced Esophageal Cancer Cell Proliferation Requires Transactivation of {beta}-Adrenoceptors J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 69 - 75. [Abstract] [Full Text] [PDF]

				D. Gallo, G. F. Zannoni, I. De Stefano, M. Mosca, C. Ferlini, E. Mantuano, and G. Scambia Soy Phytochemicals Decrease Nonsmall Cell Lung Cancer Growth In Female Athymic Mice J. Nutr., July 1, 2008; 138(7): 1360 - 1364. [Abstract] [Full Text] [PDF]

				Y. Shintani, M. Maeda, N. Chaika, K. R. Johnson, and M. J. Wheelock Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor Signaling Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 95 - 104. [Abstract] [Full Text] [PDF]

				S. C. Kiley and R. L. Chevalier Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF Am J Physiol Renal Physiol, September 1, 2007; 293(3): F895 - F903. [Abstract] [Full Text] [PDF]

				C.-W. D. Tzeng, A. Frolov, N. Frolova, N. C. Jhala, J. H. Howard, S. M. Vickers, D. J. Buchsbaum, M. J. Heslin, and J. P. Arnoletti Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response Ann. Surg. Oncol., July 1, 2007; 14(7): 2150 - 2158. [Abstract] [Full Text] [PDF]

				R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231. [Abstract] [Full Text] [PDF]